Welichem Begins Patient Enrollment for Phase IIb Trial of WBI-1001 Creams in Patients with Atopic Dermatitis
Welichem announced that the Company has begun to enroll patients in a Phase IIb clinical trial with its lead candidate, WBI-1001. The Phase IIb clinical trial is a double-blinded, placebo-controlled, 12-week-treatment study. The objectives of the trial are to evaluate the efficacy of the creams (0.5% and 1.0% WBI-1001) in comparison to the vehicle and also to evaluate the safety and tolerability of the creams in patients with atopic dermatitis.
The study is being conducted at three centers across Canada. It is planned that 150 patients will be enrolled in the trial that is anticipated to be concluded in 6 to 9 months.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Heptares enters a research and drug discovery collaboration with Juntendo University

FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant - "These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"
Foot-and-mouth_disease

Bacterial protein structure could aid development of new antibiotics

Fountain of youth for ageing stem cells in bone marrow - Epigenetic changes in old age increase risk of osteoporosis and bone fractures

Winners of the “Renewable Material of the Year 2023” Innovation Award - Biodegradable elastic materials based on food waste, carbon-light yeast oil, and a plastic-free natural polymer
Scientists identify genetic cause of previously undefined primary immune deficiency disease
Compound identified that protects against neurodegeneration
